CompletedNCT02979340
MRI to Characterize and Predict CF Liver Disease in PUSH Cohort
Studying Cystic fibrosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Principal Investigator
- Ed Doo, MDNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Intervention
- MRI(procedure)
- Enrollment
- 115 enrolled
- Eligibility
- 6-26 years · All sexes
- Timeline
- 2017 – 2019
Study locations (8)
- Children's Hospital Colorado, Aurora, Colorado, United States
- Children's Healthcare of Atlanta, Atlanta, Georgia, United States
- Riley Hospital for Children, Indianapolis, Indiana, United States
- Johns Hopkins School of Medicine, Baltimore, Maryland, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- Cincinnati Children's Hospital Medical, Cincinnati, Ohio, United States
- Texas Children's Hospital, Houston, Texas, United States
- Seattle Children's Hospital, Seattle, Washington, United States
Collaborators
Cystic Fibrosis Foundation
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02979340 on ClinicalTrials.govOther trials for Cystic fibrosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07437105Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy ParticipantsVertex Pharmaceuticals Incorporated
- RECRUITINGNANCT07436351ACT With CF Self-Help ToolkitThomas Jefferson University
- RECRUITINGNCT07369414Environmental Reservoirs of Non-tuberculous Mycobacteria in Cystic Fibrosis Households: A Case-control Study of Exposure Risk at HomeResearch Center Borstel
- RECRUITINGNANCT07314229Prevalence of Exercise-induced Ventilatory Limitation and Associated Factors in Patients With Cystic Fibrosis Receiving Elexacaftor-Tezacaftor-IvacaftorUniversity Hospital, Lille
- RECRUITINGNCT07083557Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)Bettina Mittendorfer
- RECRUITINGNCT07505797ATUSA Ultrasound Diagnostic Imaging for Breast Lesions Evaluation (AUDIBLE)iSono Health, Inc.
- RECRUITINGPHASE1NCT07283770Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy ParticipantsVertex Pharmaceuticals Incorporated
- RECRUITINGNCT07363304Impact of Elexacaftor-Tezacaftor-Ivacaftor Treatment on Metabolic, Epigenetic and Fecal Microbiota Profiles in People With Cystic Fibrosis.Meyer Children's Hospital IRCCS